• 2008

Company Description

Pathway Therapeutics develops selective inhibitors of PI3-kinase for the treatment of cancer and inflammatory diseases.

Pathway Therapeutics is focused on the discovery and development of best in class isoform selective inhibitors of PI3-kinase (PI3K) for the treatment of cancer and inflammatory diseases in targeted patient populations most likely to benefit.